COMMAND DASHBOARD
Company snapshot: $1.3B revenue, $1.3B funding, ~3,800 headcount, ~$6.1B market cap. Multi-quarter sales force disruptions from Paige and Ambry acquisitions creating GTM efficiency drag.
Integration challenges: Sales force disruptions from restructurings and acquisitions (Paige, Ambry) requiring multi-quarter recovery. Integration costs slowing go-to-market efficiency across diagnostic and AI product lines.
Financial pressures: High SG&A expenses and debt burden combined with reimbursement pressures for AI-powered diagnostic tests. Need to achieve 15% EBITDA margin by Q4 while managing cost structure.
Competitive positioning: Competing against Foundation Medicine (Roche tissue), Guardant (liquid biopsy), Caris, NeoGenomics in diagnostics; Flatiron/IQVIA/ConcertAI in data. Leading in multimodal AI/data but facing reimbursement battles and slower profitability.
Revenue diversification: Three revenue streams: diagnostic testing, data licensing, and AI applications. Data licensing showing strong growth potential (+30% target) while diagnostic reimbursement remains challenging.

Tempus AI's revenue organization is fragmented across acquisitions without unified GTM processes, systematic cross-selling infrastructure, or automated reimbursement advocacy. The company has world-class AI and data assets but lacks the commercial machine to convert multimodal capabilities into predictable enterprise contracts and sustainable diagnostic margins.

Days 1–90Q1 — STABILIZE
Days 91–180Q2 — EXPAND
Days 181–270Q3 — SCALE
Days 271–365Q4 — OPTIMIZE
Conservative

$1.4B annual revenue with 12% EBITDA margin

Target

$1.5B annual revenue with 15% EBITDA margin

Stretch

$1.7B annual revenue with 18% EBITDA margin (assumes major reimbursement wins and enterprise data deals)

Strategic Summary

Core Opportunity

Tempus AI has $6.1B market cap and leading multimodal AI/data capabilities but fragmented revenue operations across acquisitions and reimbursement pressures limiting diagnostic margins. No unified commercial infrastructure exists to convert AI leadership into predictable enterprise revenue.

Execution Thesis

Deploy integrated revenue operations across diagnostic testing, data licensing, and AI applications with automated reimbursement advocacy and cross-selling intelligence to achieve $1.5B revenue with 15% EBITDA margins — building the commercial machine that justifies the precision medicine platform valuation.

Production systems, not theory. Revenue captured, not demos given.